Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA User Fee Proposal Calls For Funding Of Risk Management “Toolkit”

Executive Summary

The Office of Drug Safety's user fee proposal includes funding for the risk management "toolkit" collaboration between FDA and the Pharmaceutical Research & Manufacturers of America

You may also be interested in...



FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters

FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review

FDA Rx Risk Assessment Guidance May Detail Lab Test Parameters

FDA's risk assessment working group is considering developing specific recommendations on which lab test results could signal safety problems for drugs under review

PDUFA III Critics Face Uphill Fight To Keep Bill Out Of Bioterrorism Package

Critics of the PDUFA III compromise are facing an uphill struggle to keep the bill out of the bioterrorism conference agreement

Related Content

UsernamePublicRestriction

Register

PS039173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel